A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma

Launched by CARSGEN THERAPEUTICS CO., LTD. · Oct 24, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called zevorcabtagene autoleucel (often shortened to zevor-cel) for people with relapsed or refractory multiple myeloma, which means their cancer has returned or didn’t respond to previous treatments. The study will observe how well this treatment works and how safe it is in real-world settings, outside of controlled clinical trials. It is being conducted at multiple centers and is open to adults aged 18 and older who qualify for the treatment.

To be eligible for this study, participants must have been diagnosed with relapsed or refractory multiple myeloma and have already received the zevor-cel infusion. It's important that those interested are willing to participate voluntarily and sign an informed consent form, which explains the study in detail. Since this is an observational study, participants can expect to receive the zevor-cel treatment as part of their care, while the researchers will gather information about their experiences and health outcomes during the process. This study is not yet recruiting participants, but it aims to provide valuable insights into the effectiveness of zevor-cel in treating multiple myeloma in everyday clinical practice.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years;
• • 2. Subjects with refractory/relapsed multiple myeloma who meet product indication criteria and have received commercialized zevor-cel infusion.
• • 3. Voluntary participation in this study and willingness to sign the informed consent form, for subjects incapable to provide consent, informed consent must be obtained from their legally acceptable guardians.
• Exclusion Criteria:
• • 1. There were no specific exclusion criteria for this study。